AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook

Key TakeawaysAbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation.The demand for those two treatments offset continuing falling sales of its former blockbuster medicine, Humira.AbbVie raised its long-term outlook for Skyrizi and Rinvoq revenue. AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better-than-expected sales and gave strong guidance on higher demand for two of its drugs to tr ...